echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Bevacizumab injection, a subsidiary of Hengrui Pharmaceuticals, obtained the approval notice of drug supplement application

    Bevacizumab injection, a subsidiary of Hengrui Pharmaceuticals, obtained the approval notice of drug supplement application

    • Last Update: 2021-10-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 27, Hengrui Pharmaceuticals issued an announcement stating that its subsidiary Shengdia Biotechnology received the approval of the State Food and Drug Administration to issue the "Drug Supplementary Application Approval Notice" for bevacizumab injection.


    Bevacizumab is a humanized anti-VEGF monoclonal antibody, developed by Chugai Pharmaceutical and Roche’s subsidiary Genentech.


    After querying the EvaluatePharma database, Avastin's global sales in 2020 are approximately US$5.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.